In melanoma, however, this association is only significant for BRAFV600E mutant tumors, suggesting a role of SLC35B2 particularly in the context of MAPKi treatment which represents a standard treatment in advanced BRAFV600 mutant, but not BRAF wildtype melanoma. Here, BRAF is linked to melanoma.